Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery

EnnovaBio

Status and phase: Enrolling; Phase 2

Conditions: Cardiac Surgery Associated - Acute Kidney Injury

Treatments: Drug: Placebo; Drug: ENN0403 capsules, high dose; Drug: ENN0403 capsules, low dose

Study type: Interventional

Funder types: Industry

Identifiers

NCT06632613

ENN0403-P2-CN-02

Details and patient eligibility

About

The is a two-stage study. Stage 1 is to evaluate the safety, tolerability, PK and PD of ENN0403 in patients at high risk of AKI following elective cardiac surgery requring cardiopulmonary bypass. Stage 2 is to evaluate the efficacy, safety, PK and PD of ENN0403 to prevent and treat AKI after multiple administraions in patients at high risk of AKI following elective cardiac surgery requring cardiopulmonary bypass.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to understand and comply with the study requirements and able to provide written informed consent;
2. Age ≥18 and ≤85 years;
3. Male subjects (and their fertile female spouses/partners) do not have pregnancy plans during the screening period and within 3 months after the last dose, voluntarily take highly effective contraception, and must not donate sperm or ova. Only non-fertile women will be enrolled, and female subjects who meet the following criteria are not considered fertile: Postmenopausal status has been achieved, normal menstruation has stopped for at least 12 consecutive months with an FSH >30 IU/L in the absence of other pathophysiological causes, or there is a medical record showing hysterectomy \ bilateral tubal resection and/or bilateral ovariectomy.
4. Subjects must be scheduled for cardiac surgery requring cardiopulmonary bypass: Coronary artery bypass grafting (CABG) and/or heart valve surgery and/or aortic root, ascending aorta and aortic arch surgery;
5. Subjects have the risk of developing AKI with at least one of the following criteria: coronary artery bypass grafting combined with one or more heart valves surgery plus at least one risk factor for AKI; Multiple heart valves surgery plus at least one AKI risk factor; Coronary artery bypass grafting or aortic valve surgery combined with aortic root, ascending aorta, and aortic arch surgery (non-aortic dissection) plus at least one risk factor for AKI; Coronary artery bypass grafting alone or single heart valve surgery plus at least 2 risk factors for AKI.

Exclusion criteria

1. Receive ICD or permanent pacemaker implantation, mechanical ventilation, IABP, LVAD or other mechanical circulatory AIDS within 1 week before surgery;
2. Cardiopulmonary resuscitation is performed within 14 days prior to screening;
3. Abnormal renal function with eGFR<20 mL/min/1.73 m2 within 30 days before screening;
4. Receive renal replacement therapy or the presence of AKI within 30 days before surgery, except for transient (≤5 days) stage 1 AKI after iodized contrast agent exposure;
5. Participate in other clinical trials within the past 1 month;
6. Have a known allergy to investigational drug or any of its constituents, or allery to any constituents used during the study;
7. Subjects with intractable hypotension, severe hypoxemia or other emergency during surgery.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

200 participants in 3 patient groups

ENN0403 capsules, low dose

Experimental group

Treatment:

Drug: ENN0403 capsules, low dose

ENN0403 capsules, high dose

Experimental group

Treatment:

Drug: ENN0403 capsules, high dose

Placebo

Experimental group

Treatment:

Drug: Placebo